Shield Therapeutics Raises €8.2 million from Inventages Venture Capital via Series A Institutional Round

1 Jun 2011

Shield Therapeutics (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage hospital pharmaceuticals, today announces that it has successfully raised €8.2m (CHF10m/US$12m) from Inventages Venture Capital (Inventages) in its first institutional (Series A) financing round.

“We are delighted to have successfully completed this fundraising which serves as further validation of the potential of ST10-021 as a novel treatment for iron deficiency anaemia and Shield’s development strategy.

Back to news